This medicine is now known as imlifidase.
On 12 January 2017, orphan designation (EU/3/16/1826) was granted by the European Commission to Hansa Medical AB, Sweden, for recombinant IgG degrading enzyme of Streptococcus pyogenes (also known as HMED-Ides) for the prevention of graft rejection following solid organ transplantation.
In February, Hansa Medical AB changed name to Hansa Biopharma AB.
Recombinant IgG degrading enzyme of Streptococcus pyogenes has been authorised in the EU as Idefirix since 25 August 2020.
Recombinant IgG degrading enzyme of Streptococcus pyogenes (imlifidase)
Prevention of graft rejection following solid organ transplantation
|Orphan designation status||
|EU designation number||
|Date of designation||
Review of designation
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: